1.12
前日終値:
$1.09
開ける:
$1.07
24時間の取引高:
8.08M
Relative Volume:
2.67
時価総額:
$124.14M
収益:
$13.45M
当期純損益:
$-178.23M
株価収益率:
-0.6788
EPS:
-1.65
ネットキャッシュフロー:
$-132.53M
1週間 パフォーマンス:
-21.13%
1か月 パフォーマンス:
-13.85%
6か月 パフォーマンス:
-68.09%
1年 パフォーマンス:
-84.31%
Fate Therapeutics Inc Stock (FATE) Company Profile
名前
Fate Therapeutics Inc
セクター
電話
858.875.1803
住所
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
FATE を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
FATE
Fate Therapeutics Inc
|
1.12 | 124.14M | 13.45M | -178.23M | -132.53M | -1.65 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
479.79 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
698.74 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
624.67 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
246.75 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beone Medicines Ltd Adr
|
271.80 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-11-18 | アップグレード | BofA Securities | Underperform → Neutral |
2024-06-17 | アップグレード | Piper Sandler | Neutral → Overweight |
2023-03-27 | 再開されました | Wells Fargo | Equal Weight |
2023-01-24 | ダウングレード | H.C. Wainwright | Buy → Neutral |
2023-01-06 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
2023-01-06 | ダウングレード | BofA Securities | Buy → Underperform |
2023-01-06 | ダウングレード | Cowen | Outperform → Market Perform |
2023-01-06 | ダウングレード | Piper Sandler | Overweight → Neutral |
2023-01-06 | ダウングレード | Stifel | Buy → Hold |
2023-01-06 | ダウングレード | Truist | Buy → Hold |
2023-01-06 | ダウングレード | Wedbush | Outperform → Neutral |
2023-01-03 | ダウングレード | Guggenheim | Buy → Neutral |
2022-12-22 | ダウングレード | Oppenheimer | Outperform → Perform |
2022-12-15 | 開始されました | Goldman | Sell |
2022-11-04 | 再開されました | Cantor Fitzgerald | Overweight |
2022-10-10 | 開始されました | Canaccord Genuity | Buy |
2022-08-18 | 再開されました | Wells Fargo | Overweight |
2022-07-28 | 開始されました | Needham | Hold |
2022-07-11 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
2022-06-03 | 開始されました | Robert W. Baird | Neutral |
2022-02-11 | 再開されました | BMO Capital Markets | Market Perform |
2021-12-15 | アップグレード | Wedbush | Neutral → Outperform |
2021-12-07 | 開始されました | Cowen | Outperform |
2021-11-09 | アップグレード | Citigroup | Neutral → Buy |
2021-08-26 | 開始されました | Morgan Stanley | Equal-Weight |
2021-06-07 | アップグレード | H.C. Wainwright | Neutral → Buy |
2021-05-07 | アップグレード | Wedbush | Neutral → Outperform |
2021-04-26 | 再開されました | Jefferies | Buy |
2021-02-26 | 開始されました | BofA Securities | Buy |
2021-02-26 | ダウングレード | Wedbush | Outperform → Neutral |
2021-02-11 | ダウングレード | Citigroup | Buy → Neutral |
2021-01-27 | 再開されました | H.C. Wainwright | Neutral |
2020-05-13 | 開始されました | H.C. Wainwright | Buy |
2020-03-04 | 開始されました | Barclays | Overweight |
2020-01-09 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
2019-12-30 | 繰り返されました | Mizuho | Buy |
2019-12-09 | アップグレード | Wells Fargo | Market Perform → Outperform |
2019-11-12 | 開始されました | SunTrust | Buy |
2019-11-06 | ダウングレード | Wells Fargo | Outperform → Market Perform |
2019-10-01 | 開始されました | Stifel | Buy |
2019-08-09 | 開始されました | BTIG Research | Buy |
2019-07-22 | 開始されました | Cantor Fitzgerald | Overweight |
2019-07-12 | 開始されました | Oppenheimer | Outperform |
2019-06-13 | 開始されました | Mizuho | Buy |
2019-06-07 | 開始されました | ROTH Capital | Neutral |
2019-05-31 | 開始されました | Guggenheim | Buy |
2019-05-24 | 再開されました | Citigroup | Buy |
2019-03-28 | 開始されました | SVB Leerink | Outperform |
2019-01-03 | ダウングレード | Stephens | Overweight → Equal-Weight |
2018-11-05 | 開始されました | Jefferies | Buy |
2018-08-01 | 開始されました | Citigroup | Buy |
2018-03-06 | ダウングレード | H.C. Wainwright | Buy → Neutral |
すべてを表示
Fate Therapeutics Inc (FATE) 最新ニュース
NK Cell Therapy Market on Track for Exponential Growth Amid Rising Pipeline Developments | DelveInsight - GlobeNewswire Inc.
Fate Therapeutics (FATE) Projected to Post Earnings on Monday - Defense World
iTeos Therapeutics (NASDAQ:ITOS) & Fate Therapeutics (NASDAQ:FATE) Head-To-Head Analysis - Defense World
Fate Therapeutics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Q1 Earnings Estimate for FATE Issued By Leerink Partnrs - MarketBeat
Will Fate Therapeutics (FATE) Report Negative Q4 Earnings? What You Should Know - Yahoo Finance
Fate Therapeutics (FATE) Projected to Post Quarterly Earnings on Monday - MarketBeat
FY2024 Earnings Forecast for FATE Issued By Leerink Partnrs - Defense World
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Fate Therapeutics, Inc. (FATE) Investors to Deadline in Securities Class Action, Encourages Investors with Significant Losses to Contact Firm’s Attorneys - accessnewswire.com
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Consensus Rating of “Hold” from Analysts - Defense World
What is Leerink Partnrs’ Estimate for FATE Q1 Earnings? - Defense World
Fate Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire
SG Americas Securities LLC Acquires 10,511 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Navigating FATE Stock: Fate Therapeutics Inc Journey - The InvestChronicle
Analysts review Fate Therapeutics Inc’s rating - Knox Daily
CRISPR and Cas Gene Market May Set a New Epic Growth Story | Fate Therapeutics, Cellectis, Synlogic - Newstrail
Take off with Fate Therapeutics Inc (FATE): Get ready for trading - SETE News
Fate Therapeutics Inc (FATE) Stock: A Year of Market Movement, Down and Up - The InvestChronicle
Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap (FATE) - Seeking Alpha
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Fate Therapeutics Inc [FATE] Investment Appeal on the Rise - Knox Daily
We're Keeping An Eye On Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate - Yahoo Finance
Fate Therapeutics Inc (FATE)’s stock performance: a year in review - US Post News
FATE 4-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Fate Therapeutics (FATE) Investors with $100K+ Losses to Contact Firm’s Attorneys Before Mar. 22nd Deadline in Securities Class Action - ACCESS Newswire
Fate Therapeutics Inc (FATE)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Fate Therapeutics' SWOT analysis: stock poised for catalysts amid clinical progress - MSN
Fate Therapeutics Inc (NASDAQ: FATE) Is A Buzzing Hot Stock - Stocks Register
Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Sold by Assenagon Asset Management S.A. - Defense World
Equities Analysts Offer Predictions for FATE FY2025 Earnings - Defense World
Research Analysts Set Expectations for FATE FY2025 Earnings - MarketBeat
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
Fate Therapeutics, Inc. (NASDAQ:FATE) Short Interest Update - MarketBeat
JPMorgan Chase & Co. Has $6.43 Million Stake in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Bought by JPMorgan Chase & Co. - MarketBeat
Day 0 of Loss Streak for Fate Therapeutics Stock with 0% Return (vs. -20% YTD) [1/22/2025] - Trefis
Fate Therapeutics' SWOT analysis: stock poised for growth amid clinical progress - Investing.com
Fate Therapeutics’ chief legal officer Cindy Tahl sells $8,763 in stock - Investing.com Nigeria
Fate Therapeutics CEO sells shares worth $13,405 By Investing.com - Investing.com Canada
Fate Therapeutics' chief legal officer Cindy Tahl sells $8,763 in stock By Investing.com - Investing.com South Africa
Fate Therapeutics executive sells $9,269 in common stock By Investing.com - Investing.com Canada
Fate Therapeutics' chief legal officer Cindy Tahl sells $8,763 in stock - Investing.com Canada
Insider Selling: Fate Therapeutics, Inc. (NASDAQ:FATE) CEO Sells $13,405.70 in Stock - MarketBeat
Barclays PLC Has $1.49 Million Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics, Inc. Announces Retirement of J. Scott Wolchko as Treasurer, Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer - Marketscreener.com
Fate Therapeutics appoints new CEO, enters advisory pact By Investing.com - Investing.com Canada
Fate Therapeutics appoints new CEO, enters advisory pact - Investing.com
Fate Therapeutics Announces Executive Leadership Transition - TipRanks
Fate Therapeutics Inc (FATE) 財務データ
収益
当期純利益
現金流量
EPS
Fate Therapeutics Inc (FATE) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
TAHL CINDY | See Remarks |
Jan 10 '25 |
Sale |
1.55 |
5,654 |
8,764 |
336,707 |
Valamehr Bahram | President and CEO |
Jan 10 '25 |
Sale |
1.54 |
8,705 |
13,406 |
349,364 |
大文字化:
|
ボリューム (24 時間):